Kforce Clinical Research, a division of Kforce, Inc. (NASDAQ: KFRC), has won Merck & Co. Inc.'s "Outstanding Operational Award in Clinical Development" as part of Merck's 2007 Supplier Recognition Awards.
Kforce Clinical Research Wins Operational Award from Merck
TAMPA, Fla. – (Sept. 10, 2008) – Kforce Clinical Research, a division of Kforce, Inc. (NASDAQ: KFRC), has won Merck & Co. Inc.’s “Outstanding Operational Award in Clinical Development” as part of Merck's 2007 Supplier Recognition Awards. Kforce Clinical Research was one of 13 suppliers to be recognized at the pharmaceutical company’s Annual Supplier Recognition Forum at their headquarters in Whitehouse Station, N.J., on June 12.
Four years ago Merck established its “Plan to Win” program. In June of this year, Merck invited 75 suppliers to the Recognition Forum where key executives discussed Merck’s critical initiatives and these suppliers’ role in helping Merck achieve its Plan to Win. Ultimately, 13 suppliers were identified for their accomplishments in this initiative.
Kforce Clinical Research provides customized and flexible functional outsourcing solutions to the biopharmaceutical industry. It specializes in clinical monitoring, site and study management, drug safety, clinical data management, data entry, clinical programming and biostatistics. Where as other outsourcing providers either augment a company’s drug trial with people or handle all aspects of the trial, Kforce’s functional outsourcing model offers a flexible, tailored approach developed to mirror each company’s business model and address specific requirements of the drug trial itself.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.